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Katie M. Applebaum1,2, Heather H. Nelson3, Michael S. Zens4, Therese A. Stukel5, Steven K. Spencer6 and
Margaret R. Karagas4
Oral contraceptives (OCs) affect the risk of several cancers in women, but have been virtually unstudied for
squamous cell carcinoma (SCC). We examined the hypothesis that OCs influence SCC risk in a case–control
study among women and also examined whether polymorphisms in the DNA repair gene, Xeroderma
pigmentosum group D (XPD), modified the risk. Incident cases of SCC were identified by a network of
dermatologists and pathology laboratories. Population-based controls were frequency matched to cases by age
and gender (n¼ 261 SCC cases, 298 controls). Overall, OC use was associated with a 60% higher risk of SCC
(odds ratio (OR), 1.6; 95% confidence interval (95% CI): 1.0–2.5). ORs for SCC were higher among those who last
used OCs X25 years before diagnosis (OR: 2.1; 95% CI: 1.2–3.7), and among these women, SCC risk increased
with duration of use (OR forp2 years, 1.7; 95% CI: 0.9–3.5; OR for 3–6 years, 2.6; 95% CI: 1.0–6.5; OR forX7 years,
2.7; 95% CI: 0.9–8.5, Ptrend¼ 0.01). Furthermore, the XPD Lys751Gln polymorphism was a significant modifier of
the OC-SCC association (Pinteraction¼ 0.03). These findings lead us to hypothesize a potential relationship
between OCs and SCC risk, and that this could involve DNA repair pathways.
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INTRODUCTION
Squamous cell carcinoma (SCC) of the skin, one of the major
forms of non-melanoma skin cancer (NMSC), is among the
most common malignancy for whites of European ancestry
(Karagas et al., 2006), and its incidence appears to have
increased dramatically within the last several decades.
Incidence rates of SCC are higher in men than in women;
however, in recent years, the rate of increase in these
malignancies may be greater in women than in men (Karagas
et al., 2006). On the basis of a statewide surveillance system
in New Hampshire, the incidence rate for SCC had a notable
increase of 235% in men and an even greater increase of
350% in women between 1979–1980 and 1993–1994
(Karagas et al., 1999). The reasons for SCC patterns differing
by gender are not known.
Sex steroids have been widely investigated as risk factors
for a number of cancers in women, particularly cancers of
reproductive organs, including breast, endometrial, ovarian,
and cervical. Unlike these other cancers, the relationship
between NMSC and oral contraceptives (OCs) has not been
thoroughly examined. Yet, OCs affect the skin, including
acting as a photosensitizing agent by potentiating the skin’s
reaction to UV radiation, the dominant risk factor for NMSC
(Esoda, 1963; Satterthwaite, 1964; Resnik, 1967; Mathison
and Haas, 1970; Horkay et al., 1975; Sedee and Beijersber-
gen van Henegouwen, 1985; Diffey, 1986; Neumann, 1988;
Cooper and George, 2001; Silver et al., 2003). Estrogens, as
growth-promoting hormones, could enhance the risk of
NMSC (Preston-Martin et al., 1990; Williams et al., 1991).
Growth promotion is one of the crucial biological pathways
in which cellular dysregulation promotes carcinogenesis
(Hanahan and Weinberg, 2000). Keratinocytes, the cells that
give rise to NMSC, express estrogen receptors and are
thought to be estrogen responsive (Urano et al., 1995;
Pelletier and Ren, 2004; Verdier-Sevrain et al., 2004).
Moreover, it is possible that estrogen may act in concert
with known carcinogenic pathways in NMSC. One of the first
recognized NMSC susceptibility factors was diminished DNA
repair capacity brought on by coding changes in the
nucleotide excision repair (NER) genes. NER removes UV-
induced DNA lesions, including pyrimidine dimers and
6,4-photoproducts, which can lead to NMSC if not
repaired. Polymorphisms in NER genes including Xeroderma
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pigmentosum group D (XPD) have been found to modify
DNA repair capacity (Qiao et al., 2002). Although a reduced
repair phenotype has been linked to an increased risk of
NMSC (Wei et al., 1994), NER polymorphisms, including
those in XPD, have been associated with reduced risks of
NMSC in epidemiological studies (Han et al., 2005;
Applebaum et al., 2007). In this analysis, we focus on
polymorphisms in XPD because this gene has been widely
examined for its potential relationship to cancer (Manuguerra
et al., 2006) and because XPD polymorphisms have been
found to be modifiers of skin cancers (Han et al., 2005;
Millikan et al., 2006; Applebaum et al., 2007). Keratinocytes
with XPD polymorphisms (and less DNA repair) are thought
to be more likely to undergo apoptosis due to an enhanced
apoptotic response (Bowen et al., 2003). In terms of the
impact of estrogen on this process, a previous study suggested
that exogenous estrogen may modify DNA repair capacity
(Grossman and Wei, 1995), but it remains to be seen whether
a gene–environment interaction between OCs and XPD
polymorphisms would lead to an increased risk of skin
cancer in a population-based study.
To explore the hypothesis that OCs increase SCC risk, we
analyzed data on history of OC use collected as part of a
population-based case–control study among women in New
Hampshire. Furthermore, we analyzed whether an associa-
tion could be modified by common polymorphisms in XPD
(Asp312Asn and Lys751Gln).
RESULTS
Among these women, SCC cases had attained a higher level
of education, experienced more severe sunburns, and
sunbathed more than the controls (Table 1). SCC cases also
were much more likely to have fair pigmentation character-
istics than controls. Education, severe sunburns, sunbathing,
and pigment score were all significant (Po0.05) predictors of
SCC after adjusting for age.
The frequency of SCC cases ever taking OCs was slightly
higher than controls (SCC cases: 44.4%; controls: 43.3%). In
multivariate models controlling for age, education, pigment
score, sunbathing, and severe sunburns, the odds ratio (OR)
and 95% confidence interval (CI) for the association between
OCs and SCC risk was elevated (OR: 1.6; 95% CI: 1.0–2.5)
(Table 2). Marital status, parity, and body mass index were
also evaluated as potential confounders, but did not influence
the results. We examined the relationship for current and
former OC use; however, there were few current users
(n¼10).
Mean duration of use was 6.6 years (standard error¼ 5.9)
in controls and 5.9 years (standard error¼4.5) in SCC cases.
We examined whether the association varied with duration of
OC use; however, within duration categories, the odds ratio
(OR) remained the same (ORp2 years: 1.6, 95% CI: 0.9–3.0;
OR36 years: 1.6, 95% CI: 0.9–3.1; and ORX7 years: 1.6, 95%
CI: 0.9–2.8) (Table 2). By evaluating time since last use, we
found an increased risk of SCC among those who last used
OCs X25 years, which was statistically significant (OR: 2.1;
95% CI: 1.2–3.7); no association with SCC was observed
among those who took OCs more recently (OR: 1.1; 95% CI:
0.6–2.0) (Table 2). Among those who last took OCs at least 25
years ago, we observed a trend of increasing SCC risk with
duration of use compared with never users (ORp2 years: 1.7,
95% CI: 0.9–3.5; OR36 years: 2.6, 95% CI: 1.0–6.5; and
ORX7 years: 2.7, 95% CI: 0.9–8.5; Ptrend¼0.01) (Table 2).
We investigated the gene–environment interaction be-
tween OC use at least 25 years ago and the XPD
polymorphisms. Among the women who took OCs at least
25 years ago, we observed that those who did not have a
751Gln variant allele had a four-fold increased risk of SCC
(OR: 4.4; 95% CI: 1.4–13.6) relative to those who had at least
one copy of the variant allele; however, no excess risk was
observed among recent OC users, regardless of their
genotype (Pinteraction¼ 0.03) (Table 3). The association be-
tween SCC risk and the 312Asn polymorphism showed the
Table 1. Selected characteristics of SCC cases and
controls among women
SCC cases N=261 Controls N=298
n % n %
Age (years)
25–44 14 5.4 46 15.4
45–54 37 14.2 47 15.8
55–64 68 26.1 72 24.2
65–69 63 24.1 69 23.1
70–74 79 30.3 64 21.5
Education—highest level1
oCollege 102 39.1 154 51.7
College 113 43.3 99 33.2
4College 46 17.6 45 15.1
Severe sunburns1,2
0–2 123 49.8 181 63.7
X3 124 50.2 103 36.3
Pigment score1,3
Quartile 1—Dark 25 9.6 74 24.8
Quartile 2 36 13.8 75 25.2
Quartile 3 68 26.0 74 24.8
Quartile 4—Fair 132 50.6 75 25.2
Sunbaths1,4
Less 46 18.8 93 33.2
Medium 66 27.0 94 33.6
Most 132 54.1 93 33.2
SCC, squamous cell carcinoma.
1Statistically significant predictor of SCC after adjusting for age.
2Missing sunburns: 14 controls and 14 SCC cases.
3Generated using a multivariate confounder score accounting for skin
reaction to intense and repeated sunshine, color of hair, eye, and skin, and
moles on back; higher pigment score represented more fair complexion.
4Sunbaths (less: 0–30; medium: 31–583; most: X584), missing for 18
controls and 17 SCC cases.
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same pattern as the 751Gln polymorphism, which was
expected, as we have previously reported that these alleles
were in linkage disequilibrium (data not shown) (Applebaum
et al., 2007).
DISCUSSION
We observed an association between OC use and SCC risk,
with a duration-related increase among women who used
OCs X25 years before diagnosis. In addition, among these
women, we detected an interaction with the Lys751Gln
polymorphism in the DNA repair gene XPD.
Estrogen-induced keratinocyte malignancies could arise
through similar pathways that are thought to influence the
risk of other cancers, including cellular proliferation,
metabolism leading to the generation of free radicals, and
DNA adduct formation from estrogen-quinone metabolites
(Zhu and Conney, 1998; Cavalieri et al., 2000; Hilakivi-
Clarke et al., 2002). Clinically, skin changes after the intake
of OCs, including melasma, suggest that individuals have an
enhanced response to UV exposure when taking OCs
(Resnik, 1967; Mathison and Haas, 1970; Horkay et al.,
1975; Sedee and Beijersbergen van Henegouwen, 1985;
Cooper and George, 2001). Thus, there may be additional
pathways to consider for SCC. Furthermore, estrogen binds to
the estrogen receptor, a transcription factor, influencing gene
expression in cells (Urano et al., 1995; Verdier-Sevrain et al.,
2004). If the expression profiles of cells change, this may alter
susceptibility to UV carcinogenesis. Our findings of an
Table 2. Oral contraceptives and SCC: joint effects of the duration of use and time since last use
Overall Duration of use (years)
Non-user User p2 3–6 X7
Overall
SCC cases 145 116 36 33 47
Controls 169 129 39 41 47
OR1 (95% CI) Referent 1.6 (1.0, 2.5) 1.6 (0.9, 3.0) 1.6 (0.9, 3.1) 1.6 (0.9, 2.8)
Last OC use2
o24 years
SCC cases 145 57 9 15 33
Controls 169 88 15 31 42
OR1 (95% CI) Referent 1.1 (0.6–2.0) 1.1 (0.4–3.3) 0.9 (0.4–2.2) 1.2 (0.6–2.3)
X25 years
SCC cases 145 56 27 16 13
Controls 169 38 23 10 5
OR1 (95% CI) Referent 2.1 (1.2–3.7) 1.7 (0.9–3.5) 2.6 (1.0–6.5) 2.7 (0.9–8.5)
Ptrend 0.01
CI, confidence interval; OC, oral contraceptive; OR, odds ratio; SCC, squamous cell carcinoma.
1ORs controlled for age, pigmentation, sunburns, sunbaths, and education. Missing information on time since last use: one control and three SCC cases; two
additional controls missing information on both time since last use and duration of use.
2Years before diagnosis.
Table 3. Association between XPD Lys751Gln, oral contraceptives, and SCC
Last OC use X25 years XPD Lys751Gln polymorphism SCC cases N=205 (%) Controls N=225 (%) OR2 (95% CI)
No1 X1 variant alleles 85 (41.5) 105 (46.7) Referent
No variant alleles 75 (36.6) 90 (40.0) 1.1 (0.7, 1.7)
Yes X1 variant alleles 23 (11.2) 22 (9.8) Referent
No variant alleles 22 (10.7) 8 (3.5) 4.4 (1.4, 13.6)
Pinteraction=0.03
CI, confidence interval; OC, oral contraceptive; OR, odds ratio; SCC, squamous cell carcinoma.
1Subjects who did not last use OCs X25 years include never users and those who stopped within last 24 years.
2ORs controlled for age, pigmentation, sunburns, sunbaths, and education.
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interaction between the DNA repair gene, XPD, and OC use
on SCC risk are consistent with this hypothesis. Furthermore,
the direction of the XPD results are consistent with previously
published NER findings, where no elevated risk was observed
among those with variant alleles. As described earlier, this
was expected as keratinocytes with a variant allele likely
have more unrepaired DNA damage, and thus undergo
apoptosis. However, with exposure to OCs and proficient
repair, an increased SCC risk was observed.
Although plausible, a relationship between OCs and risk
of SCC requires further study, as very few epidemiological
studies have evaluated this question. A cohort study among
women in England and Scotland reported no association
between OCs and a loosely defined category of all skin
cancers other than malignant melanoma (Vessey et al., 2000).
A weakness is that the study relied on self-reported skin
cancers without histological confirmation, increasing the
likelihood of incomplete ascertainment and diagnostic
misclassification. A clinic-based study of all malignant and
non-malignant skin cancers combined reported no difference
in the percentage of controls compared with skin cancer
cases who reported ever using OCs (Wei et al., 1994).
However, the lack of histological distinction between skin
cancers limits the opportunity to observe an association,
particularly as these cancers arise from different cell types.
Overall, results from these previous studies cannot be readily
compared with our analysis in which we studied histologi-
cally confirmed, incident cases of SCC.
Findings of an excess SCC risk in relation to OC use
conceivably could be confounded by the associations
between OC use and sun-seeking behavior, that is, if women
who took OCs were more likely to spend time in the sun.
Indeed, among controls in our study, OC users had a history of
more sunburns and reported more episodes of sunbathing
than non-users (data not shown). However, after adjustment
for sunburns, additional UV exposure variables such as
sunbathing or other recreational UV exposures did not change
our risk estimates. Another issue is whether individuals who
were more susceptible to the effects of UV while taking OCs
(e.g., melasma) were more likely to either cease taking them
or change their sun-exposure behavior (e.g., by avoiding UV,
applying sunscreens). We were unable to answer these
questions directly; however, few participants in this study
reported experiencing melasma (four controls and seven SCC
cases), and their duration of OC use did not differ from those
who did not experience melasma (data not shown). Age and
education also related to both OC use and SCC. To examine
the possibility of residual confounding, we restricted to those
born in 1940 or later, but the association between OCs and
SCC was, if anything, stronger, and the association remained
even after restricting to women who had had some college
education (data not shown). Furthermore, we examined the
association within age strata but found that the relationship
between time since last use and SCC showed a doubling in
risk (data not shown). Nonetheless, residual confounding and
chance cannot be ruled out entirely.
The potencies of the estrogen and progestin components
used in OCs have changed over time along with a decrease in
the overall dose. Furthermore, there are variations in the
formulation across a 1-month cycle. A stronger association
for women who used OCsX25 years before diagnosis could
reflect the use of earlier compositions of OCs, which
contained the highest levels of estrogen (e.g., X50 mg of
estrogen); however, unfortunately we were not able to
evaluate specific doses of OCs used in this analysis.
Epidemiological studies involving complete OC histories
could help elucidate the nature of the relationship with SCC
and may provide insight into the effect of estrogen content
and dose, as well as disease latency. Additional research is
needed to determine whether more recent compositions of
OCs may also be associated with SCC.
A potential limitation of our analysis is recall bias, for
example, that cases may have better recall of their OC history
than controls. In a case–control study of breast cancer
(Nischan et al., 1993), investigators compared self-reporting
of OC use with medical records data. They found no
significant differences for breast cancer cases and controls
in their ability to report on duration of use, time since first
use, and time since last use. Given that SCC is a less-severe
cancer than breast cancer, there should be less of a concern
about reporting bias for these same variables in this study.
Alternatively, a concern may be that an association reflects
greater detection of SCCs among women who took OCs
because they may be seeking more medical treatment, in
general, than those who did not take OCs. Although this
possibility exists, there were few current users of OCs and the
association of interest was among women who last used OCs
at least 25 years ago; thus, reducing the likelihood for this
potential bias.
Our findings raise many questions regarding whether the
use of OCs is a potential risk factor for SCC among women.
More epidemiological research is needed to examine
whether the findings observed here can be replicated. In
addition, a better mechanistic understanding of OCs on
keratinocyte carcinogenesis would shed light on whether OC
use is contributing to the rising incidence rates of SCC among
women in many regions of the world.
MATERIALS AND METHODS
Study population
Cases of newly diagnosed SCC occurring among New Hampshire
residents were identified through a network of dermatologists and
pathology laboratories across New Hampshire and bordering
regions. The initial study period covered diagnosis between 1 July
1993 and 30 June 1995 (series 1) (described in Karagas et al. 1999,
2001). This study additionally included diagnoses between 1 July
1997 and 30 March 2000 (series 2). The extended survey period
encompassed all participating dermatologists from the first survey
and all new practicing dermatologists in the second period.
Eligibility criteria included being a New Hampshire resident at the
time of diagnosis, being age 25–74 years at diagnosis, having a listed
telephone number, and able to speak English. All eligible SCC cases
were selected to take part in the study. The New Hampshire
Department of Transportation provided population lists of state
residents, which were used to identify potential controls aged 25–64
years. Information on potential controls aged 65–74 years was
www.jidonline.org 2763
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obtained from the Medicare enrollment lists. Controls, who were
frequency matched to the NMSC cases, were randomly sampled
from within age (25–34, 35–44, 45–54, 55–64, 65–69, and
70–74 years) and gender strata. Controls were eligible if they
spoke English and had a listed telephone number. The study protocol
was approved by the Dartmouth College Committee for the
Protection of Human Subjects, and all participants provided
informed consent. The study adhered to the Declaration of Helsinki
protocols.
Participants were administered a detailed in-person interview at
their home by a trained interviewer. Questions pertained to time
before diagnosis for cases, whereas there was random assignment of
a reference date for controls comparable to the diagnosis date of
cases. Interviews inquired about skin sensitivity, pigmentation,
education, marital status, reproductive history, and use of OCs.
Questions on skin sensitivity and pigmentation included skin
reaction to the first strong summer sun (tan only, mild burn then
tan, burn), skin reaction to repeated sun-exposure (deep tan,
moderately tan, mild tan and peel, freckling or no tan), self-reported
hair color (dark brown/black, light brown, red, blond), self-reported
eye color (brown/black, green/hazel, blue/gray), self-reported skin
color (medium/dark, light), and the number of moles on back. For
sun-exposure histories, participants indicated time periods in their
lives (above 8 years of age) with consistent sun-exposure habits and,
for each time period, also indicated the amount of time spent in the
sun, including peak UV hours (e.g., 1000 to 1400 hours),
distinguishing between winter and summer months, time spent
sunbathing, outdoor recreational activities, and the number of severe
sunburns. From this information, a life table of sun exposures was
generated and cumulative measures of these sun exposures were
calculated for each participant. Interviews began in January 1994,
and questions regarding hormone-related factors were first asked in
September 1995. Questions included whether they had ever taken
OCs, duration of use (reported by participants as the total number of
years and months that they took OCs), and timing of use (e.g., time
since last use). To aid in recall, we provided photographs and lists of
commonly used OCs. Beginning with the second phase of the study,
participants were asked about parity, weight, and height.
Of those contacted, 324 SCC cases (80%) and 435 controls
(71.5%) agreed to take part in the study. Beginning with the first
interview containing the OCs questions, a total of 265 SCC cases and
306 controls were interviewed and 99% of these (263 SCC cases and
303 controls) answered whether they had taken OCs. Because SCC
is predominantly a disease of whites, we restricted our analysis to
whites, leaving 261 SCC cases and 298 controls to analyze for the
relationship between OCs and SCC.
XPD genotyping
At the time of interview, participants provided blood samples, which
were collected for DNA extraction. When it was not possible to
collect blood, a buccal sample was obtained. Genotyping of the
XPD polymorphisms, Asp312Asn (rs1799793) and Lys751Gln
(rs13181), was conducted using Applied Biosystems’ Taqman
chemistry (Applied Biosystems, Foster City, CA). Greater detail on
the data collection and laboratory methods has been provided
elsewhere (Applebaum et al., 2007). For quality assurance, positive
and negative controls were used in each genotyping run, and
laboratory personnel were blinded to the case–control status.
Statistical analysis
There are numerous measures of pigmentation that can influence an
individual’s sensitivity to UV radiation. These include skin reaction
to first hour of intense sun (tan only, mild burn then tan, burn), skin
reaction to repeated sunshine (deep tan, moderately tan, mild tan
and peel, freckling or no tan), hair color (dark brown/black, light
brown, red, blond), eye color (brown/black, green/hazel, blue/gray),
skin color (medium/dark, light), and the number of moles on the
back (0, 1, 2–4, X5). Using these pigment factors, we generated a
multivariate confounder score to have a comprehensive measure of
confounding by pigmentation (Miettinen, 1976; Cook and Goldman,
1989). The higher the value of this score variable, the lighter a
participant’s pigment. Lighter pigment is consistent with lower
melanin production, which in theory allows more UV exposure to
reach keratinocytes.
Unconditional logistic regression was used to generate ORs
and 95% CIs for the association between OCs with SCC.
Models controlled for age continuously and severe sunburns
categorically (0–2, X3). We also adjusted for the number of times
sunbathed (0–30, 31–583, X584) and the pigment score (quartiles),
both of which were based on the distribution in the controls. Highest
level of education achieved (less than undergraduate college,
undergraduate college, and education beyond undergraduate
college), marital status, body mass index, and parity were evaluated
as confounders.
Participants were considered ever users if they had taken OCs for
a total of at least 3 months (defined by combining information on
ever use of OCs and the total cumulative duration of use) by the time
of diagnosis for cases and the reference date for controls. Participants
who reported having never taken OCs or had taken them for o3
months were classified as never users. The analysis examined ever
use of OCs, as well as the total duration of use (p2, 3–6,X7 years),
time since last use (p24, X25 years), and ever experienced
darkening of the skin on one’s face or body while taking OCs. We
further examined duration and time since last use concurrently using
a joint effects model, with never users serving as the reference group.
An observed trend was tested using an ordinal variable and a two-
sided Wald test.
We examined the hypothesis that an association between
OCs and SCC may be influenced by DNA repair using the
Asp312Asn and Lys751Gln polymorphisms in XPD gene. A binary
variable was created indicating whether participants had 0 or X1
variant alleles for each XPD polymorphism. Because previous
studies on DNA repair polymorphisms have found carriers of variant
alleles to be at a reduced risk of NMSC, they served as the reference
category in this analysis. We tested for effect modification in a model
containing the dichotomized variables for time since last OC use
(X25 years or not), each polymorphism, and their cross-product (a
1-d.f. test).
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